Ronald Carr, OD
Optometrist · Orland Park, ILNPI 1700803269
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.1%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 30 manufacturers reported payments, led by Rxsight Inc at 42.3% of the total. Reporting peaked in 2023 at $12,453 and has fallen 85.5% since, to $1,806 in 2025. Among optometrist clinicians in IL with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 344 payments — averaging $86.05 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Rxsight Inc$13K
- Kala Pharmaceuticals, Inc.$7K
- Alcon$3K
- Biotissue Holdings Inc.$1K
- Sun Pharmaceutical Industries Inc.$1K
- Bausch & Lomb Americas Inc.$845
- plus $4K from 24 others
Across 2 payments — averaging $21,000 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Rxsight Inc$42K
What the payments were for
- Consulting fees$15,99954%
- Speaking & faculty fees$1,4075%
- Travel & lodging$1,8226%
- Food & beverage$10,33635%
- Education$360%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Rxsight Inc | 37 | $12,515 |
| Kala Pharmaceuticals, Inc. | 32 | $6,923 |
| Alcon | 62 | $3,026 |
| Biotissue Holdings Inc. | 12 | $1,260 |
| Sun Pharmaceutical Industries Inc. | 25 | $1,074 |
| Bausch & Lomb Americas Inc. | 24 | $845 |
| AbbVie(2 entities) | 44 | $793 |
| Glaukos Corporation | 6 | $447 |
| Novartis | 18 | $303 |
| Tarsus Pharmaceuticals, Inc. | 4 | $277 |
| Harrow Eye, LLC | 10 | $270 |
| Dompe US, Inc. | 6 | $235 |
| Notal Vision, Inc. | 1 | $207 |
| Johnson & Johnson Surgical Vision, Inc. | 6 | $203 |
| Aerie Pharmaceuticals, Inc. | 6 | $200 |
| Bausch & Lomb, A Division Of Bausch Health US, LLC | 12 | $198 |
| Eyevance Pharmaceuticals LLC | 8 | $120 |
| Thea Pharma Inc. | 6 | $118 |
| Coopervision Inc. | 2 | $108 |
| Sight Sciences, Inc. | 7 | $101 |
| Oyster Point Pharma, Inc. | 4 | $91 |
| Lensar, Inc. | 2 | $61 |
| ABB Con-cise Optical Group LLC | 1 | $54 |
| Shire North American Group Inc | 2 | $40 |
| Optos, Inc. | 2 | $33 |
| Tearlab Corp | 1 | $25 |
| Staar Surgical Company | 1 | $25 |
| Johnson & Johnson Vision Care, Inc. | 1 | $23 |
| Carl Zeiss Meditec, Inc. | 1 | $21 |
| NEW World Medical,inc. | 1 | $2 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- RXSIGHT CONTACT LENS$11,449
- RXSIGHT INJECTOR CARTRIDGE$11,449
- RXSIGHT INJECTOR HANDPIECE$11,449
- RXSIGHT LIGHT DELIVERY DEVICE (LDD)$11,449
- RXSIGHT LIGHT ADJUSTABLE LENS (RXLAL)$9,324
- EYSUVIS$6,578
- LIGHT ADJUSTABLE LENS (LAL)$2,125
- CEQUA$555
- XELPROS$409
- DAILIES$394
- INVELTYS$250
- Hydrus Microstent$249
- enVista MX60 IOL$228
- AcrySof IQ VIVITY IOL$145
- BROMSITE$141
- VYZULTA$129
- ORA$124
- Rhopressa$121
- Rocklatan$121
- TRYPTYR$119
How this compares
$29,600 in reported general payments places this provider in the 95th percentile of 2,257 optometrist providers in Illinois.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| RestasisCyclosporine | 59 | $57,905 |
| LumiganBimatoprost | 132 | $44,192 |
| XiidraLifitegrast | 40 | $34,417 |
| VyzultaLatanoprostene Bunod | 48 | $18,333 |
| RocklatanNetarsudil Mesylat/Latanoprost | 42 | $17,767 |
| SimbrinzaBrinzolamide/Brimonidine Tart | 57 | $13,703 |
| MieboPerfluorohexyloctane/Pf | 18 | $12,987 |
| CequaCyclosporine | 14 | $11,461 |
| CombiganBrimonidine Tartrate/Timolol | 25 | $9,077 |
| Dorzolamide-TimololDorzolamide/Timolol/Pf | 48 | $8,925 |
| Brimonidine Tartrate | 82 | $7,955 |
| RhopressaNetarsudil Mesylate | 17 | $7,560 |
| Cosopt PfDorzolamide/Timolol/Pf | 21 | $7,189 |
| Prednisolone Acetate | 135 | $6,265 |
| Brinzolamide | 32 | $5,761 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieRestasis, Lumigan, Combigan, Alphagan P | $793 | $114,546229 claims |
| Bausch & Lomb Americas Inc.Xiidra, Vyzulta, Miebo | $845 | $65,737106 claims |
| Aerie Pharmaceuticals, Inc.Rocklatan, Rhopressa | $200 | $25,32759 claims |
| AlconSimbrinza | $3,026 | $13,70357 claims |
| Sun Pharmaceutical Industries Inc.Cequa | $1,074 | $11,46114 claims |
| Bausch & Lomb, A Division Of Bausch Health US, LLCLotemax Sm | $198 | $2,81311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,257 optometrist providers in Illinois.
Other optometrist in Orland Park
- Dawn TuminelloOrland Park$46K
- Pamela LoweChicago$447K
- Jeffrey LewisChampaign$394K
- Adeyinka AdewaleGodfrey$391K
- Michael ChaglasianChicago$367K
- Jessilin QuintChicago$366K
- Jullian CerasuoloChicago$329K
- Steven EidenDeerfield$259K
- Peter KehoeGalesburg$167K
- Gulroop HansraDowners Grove$151K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.